ReviewAnnals of medicine and surgery (2012)2025
Advancement in medical treatment for gastrointestinal stromal tumors (GISTs): a ray of hope.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs) present unique diagnostic and therapeutic challenges. This review highlights advancements facilitated by molecularly targeted therapies like imatinib for advanced, metastatic, and high-risk GISTs, underscoring their neoadjuvant/adjuvant utility and the importance of multidisciplinary care. Emerging avenues, including immunotherapy, PI3K/mTOR/HSP90 inhibitors, are examined, reflecting the evolving treatment landscape. Furthermore, it explores distinct clinical considerations for GIST subtypes like spindle cell, epithelioid, mixed, and SDH-deficient tumors. Crucially, identifying predictive biomarkers (molecular alterations, non-coding RNAs, SLITRK3 expression, aberrant DNA methylation, radiomics) is emphasized for optimizing individualized regimens and improving outcomes. Overall, the review highlights the remarkable advances in GIST treatment while emphasizing the need for ongoing research into novel, molecularly tailored therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.